These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 35857081)
1. [Heart and diabetes : What is the importance of GLP-1 receptor agonists in cardiology?]. Moellmann J; Lehrke M Herz; 2022 Oct; 47(5):434-441. PubMed ID: 35857081 [TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect? Li Y; Rosenblit PD Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238 [TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402 [TBL] [Abstract][Full Text] [Related]
4. GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice. Romera I; Rubio-de Santos M; Artola S; Suárez Fernández C; Conget I Adv Ther; 2023 Apr; 40(4):1418-1429. PubMed ID: 36821026 [TBL] [Abstract][Full Text] [Related]
5. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Marx N; Husain M; Lehrke M; Verma S; Sattar N Circulation; 2022 Dec; 146(24):1882-1894. PubMed ID: 36508493 [TBL] [Abstract][Full Text] [Related]
6. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study. Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA Front Public Health; 2022; 10():1031306. PubMed ID: 36408008 [TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. Wroge J; Williams NT Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946 [TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233 [TBL] [Abstract][Full Text] [Related]
9. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate. Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145 [TBL] [Abstract][Full Text] [Related]
10. Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review. Elnour AA; Al Hajri N; El Khidir IY; AlAmoodi A; Ahmed SA; Sadeq A Curr Diabetes Rev; 2020; 16(8):820-832. PubMed ID: 32442089 [TBL] [Abstract][Full Text] [Related]
17. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus]. Camafort-Babkowski M Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622 [TBL] [Abstract][Full Text] [Related]
18. Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review. Widiarti W; Sukmajaya AC; Nugraha D; Alkaff FF Diabetes Metab Syndr; 2021; 15(3):837-843. PubMed ID: 33866119 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes. De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]